In a pre-clinical model of AVM using BRAF-mutated zebrafish, treatment with the orally active inhibitor of mutated BRAF, vemurafenib, used clinically to treat BRAF-mutated metastatic melanoma, restores normal blood flow (154). The gene discussed is BRAF; the disease is metastatic melanoma.